Alecensa-话题@MedSci

#Alecensa#

3篇内容 | 599人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652060, encodeId=64011652060d8, content=<a href='/topic/show?id=9e10228601' target=_blank style='color:#2F92EE;'>#Alecensa#</a>, objectTitle=NICE支持罗氏的Alecensa, objectType=article, longId=141914, objectId=97bd14191406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bd14191406, replyNumber=0, likeNumber=39, createdTime=2018-07-31, rootId=0, userName=kksonne, userId=5b6824287634, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bd14191406, moduleTitle=NICE支持罗氏的Alecensa, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bd14191406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652059, encodeId=d6c11652059d5, content=<a href='/topic/show?id=9e10228601' target=_blank style='color:#2F92EE;'>#Alecensa#</a>, objectTitle=欧盟批准罗氏肺癌药物Alecensa最为一线用药, objectType=article, longId=124235, objectId=11a91242352e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a91242352e, replyNumber=0, likeNumber=36, createdTime=2018-08-14, rootId=0, userName=kksonne, userId=5b6824287634, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a91242352e, moduleTitle=欧盟批准罗氏肺癌药物Alecensa最为一线用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11a91242352e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652058, encodeId=04771652058d2, content=<a href='/topic/show?id=9e10228601' target=_blank style='color:#2F92EE;'>#Alecensa#</a>, objectTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, objectType=article, longId=79383, objectId=2781e9383a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2781e9383a5, replyNumber=0, likeNumber=31, createdTime=2017-08-02, rootId=0, userName=kksonne, userId=5b6824287634, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2781e9383a5, moduleTitle=重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2781e9383a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alecensa

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#Alecensa#

NICE支持罗氏的Alecensa

2018-07-31

kksonne (审核中...)

前往app查看评论内容

#Alecensa#

欧盟批准罗氏肺癌药物Alecensa最为一线用药

2018-08-14

kksonne (审核中...)

前往app查看评论内容

#Alecensa#

重磅！FDA授予罗氏抗癌药Alecensa第2个突破性药物资格，一线治疗ALK+NSCLC领域即将上演巅峰对决

2017-08-02

科室
- - 订阅+
  - 更多科室
工具
服务